Shuting Zhan, Jianfu Li, Bo Cheng, Caichen Li, Yi Feng, Lei Fan, Shan Xiong, Wenchuang Zeng, Qi Cai, Yang Xiang, Huiting Wang, Chunyan Li, Peiling Chen, Xin Zheng, Wenhai Fu, Zhexue Hao, Jianxing He, Wenhua Liang
{"title":"非小细胞肺癌中C-MET过表达的格局：基于中国数据的临床分子特征和预后的大规模研究","authors":"Shuting Zhan, Jianfu Li, Bo Cheng, Caichen Li, Yi Feng, Lei Fan, Shan Xiong, Wenchuang Zeng, Qi Cai, Yang Xiang, Huiting Wang, Chunyan Li, Peiling Chen, Xin Zheng, Wenhai Fu, Zhexue Hao, Jianxing He, Wenhua Liang","doi":"10.1177/17588359241279715","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Real-world data on C-MET protein overexpression in non-small cell lung cancer (NSCLC) patients, particularly among the Asian Chinese population, are limited.</p><p><strong>Objectives: </strong>This study aimed to evaluate the clinicomolecular characteristics and prognosis of C-MET overexpression in Chinese NSCLC patients, focusing on those with positive C-MET overexpression (immunohistochemistry (IHC) 3+).</p><p><strong>Design: </strong>A retrospective and observational study.</p><p><strong>Methods: </strong>Data were collected from NSCLC patients diagnosed at the First Affiliated Hospital of Guangzhou Medical University between November 2006 and April 2021. We identified C-MET overexpression using IHC and C-MET overexpression positivity was defined as IHC 3+ with ⩾50% tumor cells. Additionally, patient genotypes were collected for subgroup analysis.</p><p><strong>Results: </strong>Data from 9785 NSCLC patients were collected. C-MET (-) accounted for 5% (503/9785), C-MET (+) for 27% (2654/9785), C-MET (++) for 36% (3464/9785), and C-MET (+++) for 32% (3164/9785). Genetic testing was available for 4326 patients. Wild-type was observed in 37% (1591 cases), with epidermal growth factor receptor (<i>EGFR</i>) abnormalities being the most common at 49% (2127 cases). Positive C-MET overexpression correlated significantly with women (<i>p</i> < 0.001), early-stage (<i>p</i> = 0.003), adenocarcinoma (<i>p</i> < 0.001), and driver mutations (<i>p</i> < 0.001). Patients with anaplastic lymphoma kinase (<i>ALK</i>) alterations had a higher occurrence of C-MET overexpression positivity (57.1%). Positive C-MET overexpression was significantly associated with <i>EGFR</i> (<i>p</i> < 0.001), <i>ALK</i> (<i>p</i> < 0.001), and <i>KRAS</i> alterations (<i>p</i> = 0.024). Compared to C-MET overexpression (IHC 0), C-MET overexpression (IHC 2+) (hazard ratio (HR) = 0.455, <i>p</i> < 0.001) and C-MET overexpression (IHC 3+) (HR = 0.569, <i>p</i> < 0.001) were correlated with better overall survival in overall NSCLC patients, especially for C-MET overexpression (IHC 2+).</p><p><strong>Conclusion: </strong>Our study elucidates the clinicomolecular characteristics and prognosis of C-MET overexpression in NSCLC patients, particularly those with positive C-MET overexpression (IHC 3+). This provides insight into the prevalence of C-MET overexpression in Chinese NSCLC patients and offers a basis for considering C-MET overexpression as a prognostic and predictive marker in NSCLC.</p>","PeriodicalId":23053,"journal":{"name":"Therapeutic Advances in Medical Oncology","volume":"16 ","pages":"17588359241279715"},"PeriodicalIF":4.3000,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11452854/pdf/","citationCount":"0","resultStr":"{\"title\":\"Landscape of C-MET overexpression in non-small cell lung cancer: a large-scale study of clinicomolecular features and prognosis based on Chinese data.\",\"authors\":\"Shuting Zhan, Jianfu Li, Bo Cheng, Caichen Li, Yi Feng, Lei Fan, Shan Xiong, Wenchuang Zeng, Qi Cai, Yang Xiang, Huiting Wang, Chunyan Li, Peiling Chen, Xin Zheng, Wenhai Fu, Zhexue Hao, Jianxing He, Wenhua Liang\",\"doi\":\"10.1177/17588359241279715\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Real-world data on C-MET protein overexpression in non-small cell lung cancer (NSCLC) patients, particularly among the Asian Chinese population, are limited.</p><p><strong>Objectives: </strong>This study aimed to evaluate the clinicomolecular characteristics and prognosis of C-MET overexpression in Chinese NSCLC patients, focusing on those with positive C-MET overexpression (immunohistochemistry (IHC) 3+).</p><p><strong>Design: </strong>A retrospective and observational study.</p><p><strong>Methods: </strong>Data were collected from NSCLC patients diagnosed at the First Affiliated Hospital of Guangzhou Medical University between November 2006 and April 2021. We identified C-MET overexpression using IHC and C-MET overexpression positivity was defined as IHC 3+ with ⩾50% tumor cells. Additionally, patient genotypes were collected for subgroup analysis.</p><p><strong>Results: </strong>Data from 9785 NSCLC patients were collected. C-MET (-) accounted for 5% (503/9785), C-MET (+) for 27% (2654/9785), C-MET (++) for 36% (3464/9785), and C-MET (+++) for 32% (3164/9785). Genetic testing was available for 4326 patients. Wild-type was observed in 37% (1591 cases), with epidermal growth factor receptor (<i>EGFR</i>) abnormalities being the most common at 49% (2127 cases). Positive C-MET overexpression correlated significantly with women (<i>p</i> < 0.001), early-stage (<i>p</i> = 0.003), adenocarcinoma (<i>p</i> < 0.001), and driver mutations (<i>p</i> < 0.001). Patients with anaplastic lymphoma kinase (<i>ALK</i>) alterations had a higher occurrence of C-MET overexpression positivity (57.1%). Positive C-MET overexpression was significantly associated with <i>EGFR</i> (<i>p</i> < 0.001), <i>ALK</i> (<i>p</i> < 0.001), and <i>KRAS</i> alterations (<i>p</i> = 0.024). Compared to C-MET overexpression (IHC 0), C-MET overexpression (IHC 2+) (hazard ratio (HR) = 0.455, <i>p</i> < 0.001) and C-MET overexpression (IHC 3+) (HR = 0.569, <i>p</i> < 0.001) were correlated with better overall survival in overall NSCLC patients, especially for C-MET overexpression (IHC 2+).</p><p><strong>Conclusion: </strong>Our study elucidates the clinicomolecular characteristics and prognosis of C-MET overexpression in NSCLC patients, particularly those with positive C-MET overexpression (IHC 3+). This provides insight into the prevalence of C-MET overexpression in Chinese NSCLC patients and offers a basis for considering C-MET overexpression as a prognostic and predictive marker in NSCLC.</p>\",\"PeriodicalId\":23053,\"journal\":{\"name\":\"Therapeutic Advances in Medical Oncology\",\"volume\":\"16 \",\"pages\":\"17588359241279715\"},\"PeriodicalIF\":4.3000,\"publicationDate\":\"2024-09-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11452854/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Therapeutic Advances in Medical Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/17588359241279715\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Medical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/17588359241279715","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景：关于非小细胞肺癌（NSCLC）患者C-MET蛋白过表达的真实世界数据有限，尤其是在亚洲华人群体中：关于非小细胞肺癌（NSCLC）患者C-MET蛋白过表达的真实世界数据有限，尤其是在亚洲华裔人群中：本研究旨在评估中国非小细胞肺癌患者C-MET蛋白过表达的临床分子特征和预后，重点关注C-MET蛋白过表达阳性（免疫组化（IHC）3+）的患者：设计：一项回顾性观察研究：数据来自2006年11月至2021年4月期间在广州医科大学附属第一医院确诊的NSCLC患者。我们使用IHC鉴定C-MET过表达，C-MET过表达阳性定义为IHC 3+且肿瘤细胞占50%。此外，还收集了患者的基因型以进行亚组分析：结果：共收集了9785名NSCLC患者的数据。C-MET（-）占5%（503/9785），C-MET（+）占27%（2654/9785），C-MET（++）占36%（3464/9785），C-MET（+++）占32%（3164/9785）。4326 名患者接受了基因检测。野生型占 37%（1591 例），表皮生长因子受体（EGFR）异常最常见，占 49%（2127 例）。C-MET 过表达阳性与女性有显著相关性（P P = 0.003），腺癌（P P ALK）改变的 C-MET 过表达阳性发生率更高（57.1%）。C-MET过表达阳性与表皮生长因子受体（EGFR）（p ALK）（p KRAS）改变明显相关（p = 0.024）。与C-MET过表达（IHC 0）相比，C-MET过表达（IHC 2+）（危险比（HR）= 0.455，p p 结论：我们的研究阐明了NSCLC患者C-MET过表达的临床分子特征和预后，尤其是C-MET过表达阳性（IHC 3+）的患者。这有助于了解C-MET过表达在中国NSCLC患者中的流行情况，并为将C-MET过表达作为NSCLC的预后和预测标志物提供依据。
Landscape of C-MET overexpression in non-small cell lung cancer: a large-scale study of clinicomolecular features and prognosis based on Chinese data.
Background: Real-world data on C-MET protein overexpression in non-small cell lung cancer (NSCLC) patients, particularly among the Asian Chinese population, are limited.
Objectives: This study aimed to evaluate the clinicomolecular characteristics and prognosis of C-MET overexpression in Chinese NSCLC patients, focusing on those with positive C-MET overexpression (immunohistochemistry (IHC) 3+).
Design: A retrospective and observational study.
Methods: Data were collected from NSCLC patients diagnosed at the First Affiliated Hospital of Guangzhou Medical University between November 2006 and April 2021. We identified C-MET overexpression using IHC and C-MET overexpression positivity was defined as IHC 3+ with ⩾50% tumor cells. Additionally, patient genotypes were collected for subgroup analysis.
Results: Data from 9785 NSCLC patients were collected. C-MET (-) accounted for 5% (503/9785), C-MET (+) for 27% (2654/9785), C-MET (++) for 36% (3464/9785), and C-MET (+++) for 32% (3164/9785). Genetic testing was available for 4326 patients. Wild-type was observed in 37% (1591 cases), with epidermal growth factor receptor (EGFR) abnormalities being the most common at 49% (2127 cases). Positive C-MET overexpression correlated significantly with women (p < 0.001), early-stage (p = 0.003), adenocarcinoma (p < 0.001), and driver mutations (p < 0.001). Patients with anaplastic lymphoma kinase (ALK) alterations had a higher occurrence of C-MET overexpression positivity (57.1%). Positive C-MET overexpression was significantly associated with EGFR (p < 0.001), ALK (p < 0.001), and KRAS alterations (p = 0.024). Compared to C-MET overexpression (IHC 0), C-MET overexpression (IHC 2+) (hazard ratio (HR) = 0.455, p < 0.001) and C-MET overexpression (IHC 3+) (HR = 0.569, p < 0.001) were correlated with better overall survival in overall NSCLC patients, especially for C-MET overexpression (IHC 2+).
Conclusion: Our study elucidates the clinicomolecular characteristics and prognosis of C-MET overexpression in NSCLC patients, particularly those with positive C-MET overexpression (IHC 3+). This provides insight into the prevalence of C-MET overexpression in Chinese NSCLC patients and offers a basis for considering C-MET overexpression as a prognostic and predictive marker in NSCLC.
期刊介绍：
Therapeutic Advances in Medical Oncology is an open access, peer-reviewed journal delivering the highest quality articles, reviews, and scholarly comment on pioneering efforts and innovative studies in the medical treatment of cancer. The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers in medical oncology, providing a forum in print and online for publishing the highest quality articles in this area. This journal is a member of the Committee on Publication Ethics (COPE).
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
